Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 412

1.

Cancer, Burkitt Lymphoma.

Graham BS, Lynch DT.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2019 Feb 15.

2.

Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas.

Adney DR, Wang L, van Doremalen N, Shi W, Zhang Y, Kong WP, Miller MR, Bushmaker T, Scott D, de Wit E, Modjarrad K, Petrovsky N, Graham BS, Bowen RA, Munster VJ.

Viruses. 2019 Mar 2;11(3). pii: E212. doi: 10.3390/v11030212.

3.

Epitope-Specific Serological Assays for RSV: Conformation Matters.

Phung E, Chang LA, Morabito KM, Kanekiyo M, Chen M, Nair D, Kumar A, Chen GL, Ledgerwood JE, Graham BS, Ruckwardt TJ.

Vaccines (Basel). 2019 Feb 23;7(1). pii: E23. doi: 10.3390/vaccines7010023.

4.

Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages.

Corbett KS, Moin SM, Yassine HM, Cagigi A, Kanekiyo M, Boyoglu-Barnum S, Myers SI, Tsybovsky Y, Wheatley AK, Schramm CA, Gillespie RA, Shi W, Wang L, Zhang Y, Andrews SF, Joyce MG, Crank MC, Douek DC, McDermott AB, Mascola JR, Graham BS, Boyington JC.

MBio. 2019 Feb 26;10(1). pii: e02810-18. doi: 10.1128/mBio.02810-18.

5.

Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen.

Sesterhenn F, Galloux M, Vollers SS, Csepregi L, Yang C, Descamps D, Bonet J, Friedensohn S, Gainza P, Corthésy P, Chen M, Rosset S, Rameix-Welti MA, Éléouët JF, Reddy ST, Graham BS, Riffault S, Correia BE.

PLoS Biol. 2019 Feb 21;17(2):e3000164. doi: 10.1371/journal.pbio.3000164. eCollection 2019 Feb.

6.

Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses.

Kanekiyo M, Joyce MG, Gillespie RA, Gallagher JR, Andrews SF, Yassine HM, Wheatley AK, Fisher BE, Ambrozak DR, Creanga A, Leung K, Yang ES, Boyoglu-Barnum S, Georgiev IS, Tsybovsky Y, Prabhakaran MS, Andersen H, Kong WP, Baxa U, Zephir KL, Ledgerwood JE, Koup RA, Kwong PD, Harris AK, McDermott AB, Mascola JR, Graham BS.

Nat Immunol. 2019 Mar;20(3):362-372. doi: 10.1038/s41590-018-0305-x. Epub 2019 Feb 11.

PMID:
30742080
7.

Preparing for the Next Influenza Pandemic: The Development of a Universal Influenza Vaccine.

Crank MC, Mascola JR, Graham BS.

J Infect Dis. 2019 Jan 31. doi: 10.1093/infdis/jiz043. [Epub ahead of print] No abstract available.

PMID:
30715413
8.

Structure-Based Vaccine Antigen Design.

Graham BS, Gilman MSA, McLellan JS.

Annu Rev Med. 2019 Jan 27;70:91-104. doi: 10.1146/annurev-med-121217-094234.

PMID:
30691364
9.

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.

Gaudinski MR, Coates EE, Novik L, Widge A, Houser KV, Burch E, Holman LA, Gordon IJ, Chen GL, Carter C, Nason M, Sitar S, Yamshchikov G, Berkowitz N, Andrews C, Vazquez S, Laurencot C, Misasi J, Arnold F, Carlton K, Lawlor H, Gall J, Bailer RT, McDermott A, Capparelli E, Koup RA, Mascola JR, Graham BS, Sullivan NJ, Ledgerwood JE; VRC 608 Study team.

Lancet. 2019 Mar 2;393(10174):889-898. doi: 10.1016/S0140-6736(19)30036-4. Epub 2019 Jan 24.

PMID:
30686586
10.

A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8+ Memory T Cells.

Çuburu N, Kim R, Guittard GC, Thompson CD, Day PM, Hamm DE, Pang YS, Graham BS, Lowy DR, Schiller JT.

J Immunol. 2019 Feb 15;202(4):1250-1264. doi: 10.4049/jimmunol.1800219. Epub 2019 Jan 11.

PMID:
30635393
11.

A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection.

Yamamoto T, Masuta Y, Momota M, Kanekiyo M, Kanuma T, Takahama S, Moriishi E, Yasutomi Y, Saito T, Graham BS, Takahashi Y, Ishii KJ.

Int Immunol. 2019 Feb 15;31(2):81-90. doi: 10.1093/intimm/dxy069.

PMID:
30535055
12.

Publisher Correction: Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis.

Kirchdoerfer RN, Wang N, Pallesen J, Wrapp D, Turner HL, Cottrell CA, Corbett KS, Graham BS, McLellan JS, Ward AB.

Sci Rep. 2018 Dec 10;8(1):17823. doi: 10.1038/s41598-018-36918-8.

13.

A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry.

Rosen O, Chan LL, Abiona OM, Gough P, Wang L, Shi W, Zhang Y, Wang N, Kong WP, McLellan JS, Graham BS, Corbett KS.

J Virol Methods. 2019 Mar;265:77-83. doi: 10.1016/j.jviromet.2018.11.009. Epub 2018 Nov 20.

PMID:
30468747
14.

Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization.

Kleine-Weber H, Elzayat MT, Wang L, Graham BS, Müller MA, Drosten C, Pöhlmann S, Hoffmann M.

J Virol. 2019 Jan 4;93(2). pii: e01381-18. doi: 10.1128/JVI.01381-18. Print 2019 Jan 15.

PMID:
30404801
15.

Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization.

Zheng Q, Zhu R, Xu L, He M, Yan X, Liu D, Yin Z, Wu Y, Li Y, Yang L, Hou W, Li S, Li Z, Chen Z, Li Z, Yu H, Gu Y, Zhang J, Baker TS, Zhou ZH, Graham BS, Cheng T, Li S, Xia N.

Nat Microbiol. 2019 Jan;4(1):124-133. doi: 10.1038/s41564-018-0275-7. Epub 2018 Nov 5.

PMID:
30397341
16.

DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial.

Houser KV, Yamshchikov GV, Bellamy AR, May J, Enama ME, Sarwar U, Larkin B, Bailer RT, Koup R, Paskel M, Subbarao K, Anderson E, Bernstein DI, Creech B, Keyserling H, Spearman P, Wright PF, Graham BS, Ledgerwood JE; VRC 702 study team.

PLoS One. 2018 Nov 2;13(11):e0206837. doi: 10.1371/journal.pone.0206837. eCollection 2018.

17.

Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis.

Kirchdoerfer RN, Wang N, Pallesen J, Wrapp D, Turner HL, Cottrell CA, Corbett KS, Graham BS, McLellan JS, Ward AB.

Sci Rep. 2018 Oct 24;8(1):15701. doi: 10.1038/s41598-018-34171-7. Erratum in: Sci Rep. 2018 Dec 10;8(1):17823.

18.

Memory Inflation Drives Tissue-Resident Memory CD8+ T Cell Maintenance in the Lung After Intranasal Vaccination With Murine Cytomegalovirus.

Morabito KM, Ruckwardt TJ, Bar-Haim E, Nair D, Moin SM, Redwood AJ, Price DA, Graham BS.

Front Immunol. 2018 Aug 14;9:1861. doi: 10.3389/fimmu.2018.01861. eCollection 2018.

19.

The Morphology and Assembly of Respiratory Syncytial Virus Revealed by Cryo-Electron Tomography.

Ke Z, Dillard RS, Chirkova T, Leon F, Stobart CC, Hampton CM, Strauss JD, Rajan D, Rostad CA, Taylor JV, Yi H, Shah R, Jin M, Hartert TV, Peebles RS Jr, Graham BS, Moore ML, Anderson LJ, Wright ER.

Viruses. 2018 Aug 20;10(8). pii: E446. doi: 10.3390/v10080446.

20.

Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness.

Mazur NI, Horsley NM, Englund JA, Nederend M, Magaret A, Kumar A, Jacobino SR, de Haan CAM, Khatry SK, LeClerq SC, Steinhoff MC, Tielsch JM, Katz J, Graham BS, Bont LJ, Leusen JHW, Chu HY.

J Infect Dis. 2019 Jan 1;219(1):59-67. doi: 10.1093/infdis/jiy477.

21.

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.

Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, Horsley N, Buchholz UJ, Openshaw PJ, McLellan JS, Englund JA, Mejias A, Karron RA, Simões EA, Knezevic I, Ramilo O, Piedra PA, Chu HY, Falsey AR, Nair H, Kragten-Tabatabaie L, Greenough A, Baraldi E, Papadopoulos NG, Vekemans J, Polack FP, Powell M, Satav A, Walsh EE, Stein RT, Graham BS, Bont LJ; Respiratory Syncytial Virus Network (ReSViNET) Foundation.

Lancet Infect Dis. 2018 Oct;18(10):e295-e311. doi: 10.1016/S1473-3099(18)30292-5. Epub 2018 Jun 18. Review. Erratum in: Lancet Infect Dis. 2018 Jul 25;:.

22.

Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera.

Yassine HM, McTamney PM, Boyington JC, Ruckwardt TJ, Crank MC, Smatti MK, Ledgerwood JE, Graham BS.

Sci Rep. 2018 Jun 5;8(1):8628. doi: 10.1038/s41598-018-26538-7.

23.

Novel Vaccine Technologies: Essential Components of an Adequate Response to Emerging Viral Diseases.

Graham BS, Mascola JR, Fauci AS.

JAMA. 2018 Apr 10;319(14):1431-1432. doi: 10.1001/jama.2018.0345. No abstract available.

PMID:
29566112
24.

Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.

Wang L, Shi W, Chappell JD, Joyce MG, Zhang Y, Kanekiyo M, Becker MM, van Doremalen N, Fischer R, Wang N, Corbett KS, Choe M, Mason RD, Van Galen JG, Zhou T, Saunders KO, Tatti KM, Haynes LM, Kwong PD, Modjarrad K, Kong WP, McLellan JS, Denison MR, Munster VJ, Mascola JR, Graham BS.

J Virol. 2018 Apr 27;92(10). pii: e02002-17. doi: 10.1128/JVI.02002-17. Print 2018 May 15.

25.

A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.

Erbelding EJ, Post DJ, Stemmy EJ, Roberts PC, Augustine AD, Ferguson S, Paules CI, Graham BS, Fauci AS.

J Infect Dis. 2018 Jul 2;218(3):347-354. doi: 10.1093/infdis/jiy103.

PMID:
29506129
26.

Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens.

Georgiev IS, Joyce MG, Chen RE, Leung K, McKee K, Druz A, Van Galen JG, Kanekiyo M, Tsybovsky Y, Yang ES, Yang Y, Acharya P, Pancera M, Thomas PV, Wanninger T, Yassine HM, Baxa U, Doria-Rose NA, Cheng C, Graham BS, Mascola JR, Kwong PD.

ACS Infect Dis. 2018 May 11;4(5):788-796. doi: 10.1021/acsinfecdis.7b00192. Epub 2018 Mar 6.

PMID:
29451984
27.

Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation.

Goodwin E, Gilman MSA, Wrapp D, Chen M, Ngwuta JO, Moin SM, Bai P, Sivasubramanian A, Connor RI, Wright PF, Graham BS, McLellan JS, Walker LM.

Immunity. 2018 Feb 20;48(2):339-349.e5. doi: 10.1016/j.immuni.2018.01.005. Epub 2018 Feb 3.

28.

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.

Gaudinski MR, Coates EE, Houser KV, Chen GL, Yamshchikov G, Saunders JG, Holman LA, Gordon I, Plummer S, Hendel CS, Conan-Cibotti M, Lorenzo MG, Sitar S, Carlton K, Laurencot C, Bailer RT, Narpala S, McDermott AB, Namboodiri AM, Pandey JP, Schwartz RM, Hu Z, Koup RA, Capparelli E, Graham BS, Mascola JR, Ledgerwood JE; VRC 606 Study Team.

PLoS Med. 2018 Jan 24;15(1):e1002493. doi: 10.1371/journal.pmed.1002493. eCollection 2018 Jan.

29.

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.

Fong Y, Shen X, Ashley VC, Deal A, Seaton KE, Yu C, Grant SP, Ferrari G, deCamp AC, Bailer RT, Koup RA, Montefiori D, Haynes BF, Sarzotti-Kelsoe M, Graham BS, Carpp LN, Hammer SM, Sobieszczyk M, Karuna S, Swann E, DeJesus E, Mulligan M, Frank I, Buchbinder S, Novak RM, McElrath MJ, Kalams S, Keefer M, Frahm NA, Janes HE, Gilbert PB, Tomaras GD.

J Infect Dis. 2018 Mar 28;217(8):1280-1288. doi: 10.1093/infdis/jiy008.

30.

Functional interrogation and mining of natively paired human VH:VL antibody repertoires.

Wang B, DeKosky BJ, Timm MR, Lee J, Normandin E, Misasi J, Kong R, McDaniel JR, Delidakis G, Leigh KE, Niezold T, Choi CW, Viox EG, Fahad A, Cagigi A, Ploquin A, Leung K, Yang ES, Kong WP, Voss WN, Schmidt AG, Moody MA, Ambrozak DR, Henry AR, Laboune F, Ledgerwood JE, Graham BS, Connors M, Douek DC, Sullivan NJ, Ellington AD, Mascola JR, Georgiou G.

Nat Biotechnol. 2018 Feb;36(2):152-155. doi: 10.1038/nbt.4052. Epub 2018 Jan 8.

31.

The Zika virus envelope protein glycan loop regulates virion antigenicity.

Goo L, DeMaso CR, Pelc RS, Ledgerwood JE, Graham BS, Kuhn RJ, Pierson TC.

Virology. 2018 Feb;515:191-202. doi: 10.1016/j.virol.2017.12.032. Epub 2018 Jan 2.

32.

Recent progress in immune-based interventions to prevent HIV-1 transmission to children.

Voronin Y, Jani I, Graham BS, Cunningham CK, Mofenson LM, Musoke PM, Permar SR, Scarlatti G.

J Int AIDS Soc. 2017 Dec;20(4). doi: 10.1002/jia2.25038.

33.

Zika Virus Vaccine Development.

Morabito KM, Graham BS.

J Infect Dis. 2017 Dec 16;216(suppl_10):S957-S963. doi: 10.1093/infdis/jix464.

34.

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial.

DeZure AD, Coates EE, Hu Z, Yamshchikov GV, Zephir KL, Enama ME, Plummer SH, Gordon IJ, Kaltovich F, Andrews S, McDermott A, Crank MC, Koup RA, Schwartz RM, Bailer RT, Sun X, Mascola JR, Tumpey TM, Graham BS, Ledgerwood JE.

NPJ Vaccines. 2017 Jun 1;2:15. doi: 10.1038/s41541-017-0016-6. eCollection 2017.

35.

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.

Gilbert PB, Juraska M, deCamp AC, Karuna S, Edupuganti S, Mgodi N, Donnell DJ, Bentley C, Sista N, Andrew P, Isaacs A, Huang Y, Zhang L, Capparelli E, Kochar N, Wang J, Eshleman SH, Mayer KH, Magaret CA, Hural J, Kublin JG, Gray G, Montefiori DC, Gomez MM, Burns DN, McElrath J, Ledgerwood J, Graham BS, Mascola JR, Cohen M, Corey L.

Stat Commun Infect Dis. 2017 Jan;9(1). pii: 20160001. doi: 10.1515/scid-2016-0001. Epub 2017 Jun 6.

36.

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.

Gaudinski MR, Houser KV, Morabito KM, Hu Z, Yamshchikov G, Rothwell RS, Berkowitz N, Mendoza F, Saunders JG, Novik L, Hendel CS, Holman LA, Gordon IJ, Cox JH, Edupuganti S, McArthur MA, Rouphael NG, Lyke KE, Cummings GE, Sitar S, Bailer RT, Foreman BM, Burgomaster K, Pelc RS, Gordon DN, DeMaso CR, Dowd KA, Laurencot C, Schwartz RM, Mascola JR, Graham BS, Pierson TC, Ledgerwood JE, Chen GL; VRC 319; VRC 320 study teams.

Lancet. 2018 Feb 10;391(10120):552-562. doi: 10.1016/S0140-6736(17)33105-7. Epub 2017 Dec 5.

37.

Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic.

Graham BS, Sullivan NJ.

Nat Immunol. 2018 Jan;19(1):20-28. doi: 10.1038/s41590-017-0007-9. Epub 2017 Dec 14. Review.

PMID:
29199281
38.

Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein.

Tian D, Battles MB, Moin SM, Chen M, Modjarrad K, Kumar A, Kanekiyo M, Graepel KW, Taher NM, Hotard AL, Moore ML, Zhao M, Zheng ZZ, Xia NS, McLellan JS, Graham BS.

Nat Commun. 2017 Nov 30;8(1):1877. doi: 10.1038/s41467-017-01858-w.

39.

Corrigendum: Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.

Rossey I, Gilman MSA, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA, Graham BS, Schepens B, McLellan JS, Saelens X.

Nat Commun. 2017 Nov 29;8:16165. doi: 10.1038/ncomms16165.

40.

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

deCamp AC, Rolland M, Edlefsen PT, Sanders-Buell E, Hall B, Magaret CA, Fiore-Gartland AJ, Juraska M, Carpp LN, Karuna ST, Bose M, LePore S, Miller S, O'Sullivan A, Poltavee K, Bai H, Dommaraju K, Zhao H, Wong K, Chen L, Ahmed H, Goodman D, Tay MZ, Gottardo R, Koup RA, Bailer R, Mascola JR, Graham BS, Roederer M, O'Connell RJ, Michael NL, Robb ML, Adams E, D'Souza P, Kublin J, Corey L, Geraghty DE, Frahm N, Tomaras GD, McElrath MJ, Frenkel L, Styrchak S, Tovanabutra S, Sobieszczyk ME, Hammer SM, Kim JH, Mullins JI, Gilbert PB.

PLoS One. 2017 Nov 17;12(11):e0185959. doi: 10.1371/journal.pone.0185959. eCollection 2017.

41.

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.

Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, Ledgerwood JE, Frank I, Sobieszczyk ME, Baden LR, Rodriguez B, Van Tieu H, Tomaras GD, Deal A, Goodman D, Bailer RT, Ferrari G, Jensen R, Hural J, Graham BS, Mascola JR, Corey L, Montefiori DC; HVTN 104 Protocol Team; and the NIAID HIV Vaccine Trials Network.

PLoS Med. 2017 Nov 14;14(11):e1002435. doi: 10.1371/journal.pmed.1002435. eCollection 2017 Nov.

42.

Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus.

Sastry M, Zhang B, Chen M, Joyce MG, Kong WP, Chuang GY, Ko K, Kumar A, Silacci C, Thom M, Salazar AM, Corti D, Lanzavecchia A, Taylor G, Mascola JR, Graham BS, Kwong PD.

PLoS One. 2017 Oct 26;12(10):e0186854. doi: 10.1371/journal.pone.0186854. eCollection 2017.

43.

Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans.

Grifoni A, Pham J, Sidney J, O'Rourke PH, Paul S, Peters B, Martini SR, de Silva AD, Ricciardi MJ, Magnani DM, Silveira CGT, Maestri A, Costa PR, de-Oliveira-Pinto LM, de Azeredo EL, Damasco PV, Phillips E, Mallal S, de Silva AM, Collins M, Durbin A, Diehl SA, Cerpas C, Balmaseda A, Kuan G, Coloma J, Harris E, Crowe JE Jr, Stone M, Norris PJ, Busch M, Vivanco-Cid H, Cox J, Graham BS, Ledgerwood JE, Turtle L, Solomon T, Kallas EG, Watkins DI, Weiskopf D, Sette A.

J Virol. 2017 Oct 4. pii: JVI.01469-17. doi: 10.1128/JVI.01469-17. [Epub ahead of print]

44.

A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage.

Shan C, Muruato AE, Jagger BW, Richner J, Nunes BTD, Medeiros DBA, Xie X, Nunes JGC, Morabito KM, Kong WP, Pierson TC, Barrett AD, Weaver SC, Rossi SL, Vasconcelos PFC, Graham BS, Diamond MS, Shi PY.

Nat Commun. 2017 Sep 22;8(1):676. doi: 10.1038/s41467-017-00737-8.

45.

Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.

Liu X, Liang B, Ngwuta J, Liu X, Surman S, Lingemann M, Kwong PD, Graham BS, Collins PL, Munir S.

J Virol. 2017 Oct 27;91(22). pii: e01101-17. doi: 10.1128/JVI.01101-17. Print 2017 Nov 15.

46.

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.

Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA, Becker MM, Wang L, Shi W, Kong WP, Andres EL, Kettenbach AN, Denison MR, Chappell JD, Graham BS, Ward AB, McLellan JS.

Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357. doi: 10.1073/pnas.1707304114. Epub 2017 Aug 14.

47.

HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques.

Han Q, Williams WB, Saunders KO, Seaton KE, Wiehe KJ, Vandergrift N, Von Holle TA, Trama AM, Parks RJ, Luo K, Gurley TC, Kepler TB, Marshall DJ, Montefiori DC, Sutherland LL, Alam MS, Whitesides JF, Bowman CM, Permar SR, Graham BS, Mascola JR, Seed PC, Van Rompay KKA, Tomaras GD, Moody MA, Haynes BF.

J Virol. 2017 Oct 13;91(21). pii: e00923-17. doi: 10.1128/JVI.00923-17. Print 2017 Nov 1.

48.

Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans.

Andrews SF, Joyce MG, Chambers MJ, Gillespie RA, Kanekiyo M, Leung K, Yang ES, Tsybovsky Y, Wheatley AK, Crank MC, Boyington JC, Prabhakaran MS, Narpala SR, Chen X, Bailer RT, Chen G, Coates E, Kwong PD, Koup RA, Mascola JR, Graham BS, Ledgerwood JE, McDermott AB.

Sci Immunol. 2017 Jul 14;2(13). pii: eaan2676. doi: 10.1126/sciimmunol.aan2676.

PMID:
28783708
49.

Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Immunogenetic Considerations Underlying B-Cell Biology in the Development of a Pan-Subtype Influenza A Vaccine Targeting the Hemagglutinin Stem.

Andrews SF, Graham BS, Mascola JR, McDermott AB.

Cold Spring Harb Perspect Biol. 2018 Jul 2;10(7). pii: a029413. doi: 10.1101/cshperspect.a029413. Review.

PMID:
28663207
50.

Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.

Liang B, Ngwuta JO, Surman S, Kabatova B, Liu X, Lingemann M, Liu X, Yang L, Herbert R, Swerczek J, Chen M, Moin SM, Kumar A, McLellan JS, Kwong PD, Graham BS, Collins PL, Munir S.

J Virol. 2017 Jul 12;91(15). pii: e00189-17. doi: 10.1128/JVI.00189-17. Print 2017 Aug 1.

Supplemental Content

Loading ...
Support Center